Development of a method for detecting ctDNA in patients with non-small cell lung cancer using the RASSF1 methylation marker
https://doi.org/10.29235/1814-6023-2025-22-4-314-323
Abstract
Based on information from the international database The Cancer Genome Atlas, the methylation status of the RASSF1 gene promoter was studied in 57 non-small cell lung cancer tissue samples (adenocarcinoma and squamous cell lung carcinoma) and 27 normal lung tissue samples. Promoter regions characterized by specific methylation profiles in non-sm all cell lung cancer, including various histological types, were identified.
The obtained data was then used to design primers for methylation-specific PCR, thereby confirming the feasibility of using the RASSF1 marker for tumor DNA detection. A methodology for detecting ctDNA in the blood plasma of patients with non-small cell lung cancer was developed using droplet digital PCR.
Supporting agencies: The work was carried out within the framework of the BRFFR М-23 RSF, grant No. 131.
About the Authors
S. Y. Smirnou
N. N. Alexandrov National Cancer Centre
Belarus
Belarus
Siarhei Y. Smirnou ‒ biologist
223040, Lesnoy, Minsk region
A. V. Miadzvedz
N. N. Alexandrov National Cancer Centre
Belarus
Belarus
Antonina V. Miadzvedz ‒ doctor of clinical laboratory diagnostic
223040, Lesnoy, Minsk region
S. N. Pivavarchyk
N. N. Alexandrov National Cancer Centre
Belarus
Belarus
Siarhei N. Pivavarchyk ‒ oncologist
223040, Lesnoy, Minsk region
T. G. Vakhomchyk
N. N. Alexandrov National Cancer Centre
Belarus
Belarus
Tatsiana G. Vakhomchyk ‒ radiologist
223040, Lesnoy, Minsk region
P. E. Karatkevich
N. N. Alexandrov National Cancer Centre
Belarus
Belarus
Pavel E. Karatkevich ‒ Ph. D. (Med.), Associate Pro- fessor, Head of the Department
223040, Lesnoy, Minsk region
H. I. Subach
N. N. Alexandrov National Cancer Centre
Belarus
Belarus
Helen I. Subach ‒ Ph. D. (Med.), Associate Professor, Head of the Department
223040, Lesnoy, Minsk region
A. S. Portyanko
N. N. Alexandrov National Cancer Centre
Russian Federation
Russian Federation
Anna S. Portyanko ‒ D. Sc. (Med.), Professor, Head of the Laboratory
223040, Lesnoy, Minsk region
References
1. Malpeli G., Innamorati G., Decimo I., Bencivenga M., Kamdje A. H. N., Perris R., Bassi C. Methylation dynamics of RASSF1A and its impact on cancer. Cancers, 2019, vol. 11, no. 7, art. 959. https://doi.org/10.3390/cancers11070959
2. Dubois F., Bergot E., Zalcman G., Levallet G. RASSF1A, puppeteer of cellular homeostasis, fights tumorigenesis, and metastasis ‒ an updated review. Cell Death and Disease, 2019, vol. 10, no. 12, art. 928. https://doi.org/10.1038/s41419-019-2169-x
3. Huang Y.-Z., Wu W., Wu K., Xu X.-N., Tang W.-R. Association of RASSF1A promoter methylation with lung cancer risk: a meta-analysis. Asian Pacific Journal of Cancer Prevention, 2014, vol. 15, no. 23, pp. 10325‒10328. https://doi.org/10.7314/apjcp.2014.15.23.10325
4. Zhang N., Liu Z., Li K., Xing X., Long C., Liu F., She B., Che N. DNA methylation analysis of the SHOX2 and RASSF1A panel using cell-free DNA in the diagnosis of malignant pleural effusion. Journal of Oncology, 2023, vol. 2023, art. 5888844. https://doi.org/10.1155/2023/5888844
5. Zogchel L., Wezel E., Wijk J., Stutterheim J., Bruins W. S. C., Zappeij-Kannegieter L. [et al.]. Hypermethylated RASSF1A as circulating tumor DNA marker for disease monitoring in neuroblastoma. JCO Precision Oncology, 2020, vol. 4, pp. 291–306. https://doi.org/10.1200/PO.19.00261
6. Hu H., Zhou Y., Zhang M., Ding R. Prognostic value of RASSF1A methylation status in non-small cell lung cancer (NSCLC) patients: A meta-analysis of prospective studies. Biomarkers, 2019, vol. 24, no. 3, рр. 207‒216. https://doi.org/10.1080/1354750X.2019.1583771
7. National Cancer Institute. The Cancer Genome Atlas. Available at: https://portal.gdc.cancer.gov (accessed 12.05.2025).
8. TFsitescan. Available at: http://www.ifti.org/cgi-bin/ifti/Tfsitescan.pl (accessed 12.05.2025).
9. The Li Lab. MethPrimer 2.0. Available at: http://www.urogene.org/cgi-bin/methprimer/methprimer.cgi (accessed 12.05.2025).
10. Integrated DNA technologies. OlygoAnalyzer. Available at: https://www.idtdna.com/pages/tools/oligoanalyzer (accessed 12.05.2025).
Review
For citations:
Smirnou S.Y., Miadzvedz A.V., Pivavarchyk S.N., Vakhomchyk T.G., Karatkevich P.E., Subach H.I., Portyanko A.S. Development of a method for detecting ctDNA in patients with non-small cell lung cancer using the RASSF1 methylation marker. Proceedings of the National Academy of Sciences of Belarus, Medical series. 2025;22(4):314-323. (In Russ.) https://doi.org/10.29235/1814-6023-2025-22-4-314-323
Views:
44
Email this article 